Skip to main content
SpringerLink
Log in

Dexrazoxane (ICRF-187) protects cardiac myocytes against doxorubicin by preventing damage to mitochondria

  • Published:
Cardiovascular Toxicology Aims and scope Submit manuscript

Abstract

The clinically approved antioxidant cardioprotective agent dexrazoxane (ICRF-187) was examined for its ability to protect neonatal rat cardiac myocytes from doxorubicin-induced damage. Doxorubicin is thought to induce oxidative stress on the heart muscle, both through reductive activation to its semiquinone form, and by the production of hydroxyl radicals mediated by its complex with iron. Hydrolyzed dexrazoxane metabolites prevent site-specific iron-based oxygen radical damage by displacing iron from doxorubicin and chelating free and loosely bound iron. The mitochondrial stain Mito Tracker Green GM and doxorubicin were shown by epifluorescence microscopy to accumulate in the myocyte mitochondria. An epifluorescence microscopic image analysis method to measure mitochondrial damage was developed using the mitochondrial membrane potential sensing ratiometric dye JC-1. This method was used to show that dexrazoxane protected against doxorubicin-induced depolarization of the myocyte mitochondrial membrane. Dexrazoxane also attenuated doxorubichin-induced oxidation of intracellular dichlorofluorescin. Annexin V-FITC/propidium iodide staining of myocytes was used to demonstrate that, depending on the concentration, doxorubicin caused both apoptotic and necrotic damage. These results suggest that doxorubicin may be cardiotoxic by damaging the mitochondria and dexrazoxane may be protective by preventing iron-based oxidative damage.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Hasinoff, B. B., Hellmann, K., Herman, E. H., and Ferrans, V. J. (1998). Chemical biological and clinical aspects of dexrazoxane and other bisdioxopiperazines. Curr. Med. Chem. 5:1–28.

    PubMed  CAS  Google Scholar 

  2. Malisza, K. L. and Hasinoff, B. B. (1995). Production of hydroxyl radical by iron(III)-anthraquinone complexes through self-reduction and through reductive activation by the xanthine oxidase/hypoxanthine systems. Arch. Biochem. Biophys. 321:51–60.

    Article  PubMed  CAS  Google Scholar 

  3. Barnabé, N., Zastre, J., Venkataram, S. and Hasinoff, B. B. (2002). Deferiprone protects against doxorubicin-induced myocyte cytotoxicity. Free Radic. Biol. Med. 33:266–275.

    Article  PubMed  Google Scholar 

  4. Hasinoff, B. B. (1994). Pharmacodynamics of the hydrolysis-activation of the cardioprotective agent (+)-1,2-bis(3,5-dioxopiperazinlyl-l-yl)propane. J. Pharm. Sci. 83:64–67.

    Article  PubMed  CAS  Google Scholar 

  5. Hasinoff, B. B. (1994). An HPLC and spectrophotometric study of the hydrolysis of ICRF-187 (dexrazoxane, (+)-1,2-bis(3,5-dioxopiperazinyl-l-yl)propane) and its onering opened intermediates. Int. J. Pharmacol. 107:67–76.

    Article  CAS  Google Scholar 

  6. Diop, N. K., Vitellaro, L. K., Arnold, P., Shang, M., and Marusak, R. A. (2000). Iron complexes of the cardioprotective agent dexrazoxane (ICRF-187) and its desmethyl derivative, ICRF-154: solid state structure, solution thermodynamics, and DNA cleavage activity. J. Inorg. Biochem. 78:209–216.

    Article  PubMed  CAS  Google Scholar 

  7. Huang, Z.-X., May, P. M., Quinlan, K. M., Williams, D. R., and Creighton, A. M. (1982). Metal binding by pharmaceuticals. Part 2. Interactions of Ca(II), Cu(II), Fe(II), Mg(II), Mn(II) and Zn(II) with the intracellular hydrolysis products of the antitumor agent ICRF-159 and its inactive homologue ICRF-192. Agents Actions 12:536–542.

    Article  PubMed  CAS  Google Scholar 

  8. Buss, J. L. and Hasinoff, B. B. (1993). The one-ring open hydrolysis product intermediates of the cardioprotective agent ICRF-187 (dexrazoxane) displace iron from ironanthracycline complexes. Agents Actions 40:86–95.

    Article  PubMed  CAS  Google Scholar 

  9. Dawson, K. M. (1975). Studies on the stability and cellular distribution of dioxopiperazines in cultured BHK-21S cells. Biochem. Pharmacol. 24:2249–2253.

    Article  PubMed  CAS  Google Scholar 

  10. Jung, K. and Reszka, R. (2001). Mitochondria as subcellular targets for clinically useful anthracyclines. Adv. Drug Deliv. Rev. 49:87–105.

    Article  PubMed  CAS  Google Scholar 

  11. Hershko, C., Pinson, A., and Link, G. (1996). Prevention of anthracycline cardiotoxicity by iron chelation. Acta Haematol. 95:87–92.

    Article  PubMed  CAS  Google Scholar 

  12. Sokolove, P. M. and Shinaberry, R. G. (1988). Na+-independent release of Ca2+ from rat heart mitochondria. Biochem. Pharmacol. 37:803–812.

    Article  PubMed  CAS  Google Scholar 

  13. Gianni, L., Corden, B. J. and Myers, C. E. (1983). The biochemical basis of anthracycline toxicity and anti-tumor activity. Rev. Biochem. Toxicol. 5:1–82.

    CAS  Google Scholar 

  14. Hasinoff, B. B. and Davey, J. P. (1988). Adriamycin and its iron(III) and copper(II) complexes; glutathione-induced dissociation; cytochrome c oxidase inactivation and protection; binding to cardiolipin. Biochem. Pharmacol. 37: 3663–3669.

    Article  PubMed  CAS  Google Scholar 

  15. Goormaghtigh, E., Huart, P., Praet, M., Brasseur, R., and Ruysschaert, J.-M. (1990). Structure of the adriamycincardiolipin complex. Role in mitochondrial toxicity. Biophys. Chem. 35:247–257.

    Article  PubMed  CAS  Google Scholar 

  16. Reers, M., Smiley, S. T., Mottolla-Hartshorn, C., Chen, A., Lin, M., and Chen, L. B. (1995). Mitochondrial membrane potential monitored by JC-1 dye. Methods Enzymol. 260: 406–417.

    Article  PubMed  CAS  Google Scholar 

  17. Keij, J. F., Bell-Prince, C., and Steinkamp, J. A. (2000). Staining of mitochondrial membranes with 10-nonyl acridine orange, MitoFluor Green, and Mito Tracker Green is affected by mitochondrial membrane potential altering drugs. Cytometry 39:203–210.

    Article  PubMed  CAS  Google Scholar 

  18. Swift, L. M. and Sarvazyan, N. (2000). Localization of dichlorofluorescin in cardiac myocytes: Implications for assessment of oxidative stress. Am. J. Physiol. Heart Circ. Physiol. 278:H982-H990.

    PubMed  CAS  Google Scholar 

  19. Sarvazyan, N. (1996). Visualization of doxorubicin-induced oxidative stress in isolated cardiac myocytes. Am. J. Physiol. 271:H2079-H2085.

    PubMed  CAS  Google Scholar 

  20. Link, G., Tirosh, R., Pinson, A., and Hershko, C. (1996). Role of iron in the potentiation of anthracycline cardiotoxicity: identification of heart cell mitochondria as a major site of iron-anthracycline interaction. J. Lab. Clin. Med. 127:272–278.

    Article  PubMed  CAS  Google Scholar 

  21. Childs, A. C., Phaneuf, S. L., Dirks, A. J., Phillips, T., and Leeuwenburgh, C. (2002). Doxorubicin treatment in vivo causes cytochrome c release and cardiomyocyte apoptosis, as well as increased mitochondrial efficiency, superoxide dismutase activity, and Bcl-2: Bax ratio. Cancer Res. 62: 4592–4598.

    PubMed  CAS  Google Scholar 

  22. Kluck, R. M., Bossy-Wetzel, E., Green, D. R., and Newmeyer, D. D. (1997). The release of cytochrome c from mitochondria: A primary site for Bcl-2 regulation of apoptosis. Science 275:1132–1136.

    Article  PubMed  CAS  Google Scholar 

  23. Dunkern, T. R. and Mueller-Klieser, W. (1999). Quantification of apoptosis induction by doxorubicin in three types of human mammary carcinoma spheroids. Anticancer Res. 19:3141–3146.

    PubMed  CAS  Google Scholar 

  24. Sawyer, D. B., Fukazawa, R., Arstall, M. A., and Kelly, R. A. (1999). Daunorubicin-induced apoptosis in rat cardiac myocytes is inhibited by dexrazoxane. Circ. Res. 84: 257–265.

    PubMed  CAS  Google Scholar 

  25. Kumar, D., Kirshenbaum, L., Li, T., Danelisen, I., and Singal, P. (1999). Apoptosis in isolated adult cardiomyocytes exposed to adriamycin. Ann. N. Y. Acad. Sci. 874:156–168.

    Article  PubMed  CAS  Google Scholar 

  26. Kotamraju, S., Konorev, E. A., Joseph, J., and Kalyanaraman, B. (2000). Doxorubicin-induced apoptosis in endothelial cells and cardiomyocytes is ameliorated by nitrone spin traps and ebselen. Role of reactive oxygen and nitrogen species. J. Biol. Chem. 275:33585–33592.

    Article  PubMed  CAS  Google Scholar 

  27. Hasinoff, B. B. (2002). Dexrazoxane (ICRF-187) protects cardiac myocytes against hypoxia-reoxygenation damage. Cardiovasc. Toxicol. 2:111–118.

    Article  PubMed  CAS  Google Scholar 

  28. Malisza, K. L. and Hasinoff, B. B. (1996). Inhibition of anthracycline semiquinone formation by ICRF-187 (dexrazoxane) in cells. Free Radicals Biol. Med. 20:905–914.

    Article  CAS  Google Scholar 

  29. LeBel, C. P., Ischiropoulos, H., and Bondy, S. C. (1992). Evaluation of the probe 2′,7′-dichlorofluorescin as an indicator of reactive oxygen species formation and oxidative stress. Chem. Res. Toxicol. 5:227–231.

    Article  PubMed  CAS  Google Scholar 

  30. Rota, C., Chignell, C. F., and Mason, R. P. (1999). Evidence for free radical formation during the oxidation of 2′-7′-dichlorofluorescin to the fluorescent dye 2′–7′-dichlorofluorescein by horseradish peroxidase: possible implications for oxidative stress measurements. Free Radicals Biol. Med. 27:873–881.

    Article  CAS  Google Scholar 

  31. Kang, Y. J., Zhou, Z. X., Wang, G. W., Buridi, A., and Klein, J. B. (2000). Suppression by metallothionein of doxorubicin-induced cardiomyocyte apoptosis through inhibition of p38 mitogen-activated protein kinases. J. Biol. Chem. 275:13690–13698.

    Article  PubMed  CAS  Google Scholar 

  32. Davies, K. J. A. and Doroshow, J. H. (1986). Redox cycling of anthracyclines by cardiac mitochondria. I. Anthracycline radical formation by NADH dehydrogenases. J. Biol. Chem. 261:3060–3067.

    PubMed  CAS  Google Scholar 

  33. Myers, C. E., Mimnaugh, E. G., Yeh, G. C., and Sinha, B. K. (1988). Biochemical mechanisms of tumor cell kill by the anthracyclines. In Lown, J. W. (ed.), Anthracycline and Anthracenedione-based Anticancer Agents, vol. 6. Amsterdam: Elsevier, pp. 527–569.

    Google Scholar 

  34. Hochster, H., Liebes, L., Wadler, S., Oratz, R., Wernz, J. C., Meyers, M., Green, M., Blum, R. H., and Speyer, J. L. (1992). Pharmacokinetics of the cardioprotector ADR-529 (ICRF-187) in escalating doses combined with fixed-dose doxorubicin. J. Natl. Cancer Inst. 84:1725–1730.

    Article  PubMed  CAS  Google Scholar 

  35. Zhang, J., Clark, J. R., Herman, E. H., and Ferrans, V. J. (1996). Doxorubicin-induced apoptosis in spontaneously hypertensive rats: Differential effects in heart, kidney and intestine, and inhibition by ICRF-187. J. Mol. Cell. Cardiol. 28:1931–1943.

    Article  PubMed  CAS  Google Scholar 

  36. Herman, E. H., Zhang, J., Hasinoff, B. B., Clark, J. R. J., and Ferrans, V. J. (1997). Comparison of the structural changes induced by doxorubicin and mitoxantrone in the heart, kidney and intestine and characterization of the Fe(III)-mitoxantrone complex. J. Mol. Cell. Cardiol. 29: 2415–2430.

    Article  PubMed  CAS  Google Scholar 

  37. Hasinoff, B. B. (1993). Enzymatic ring-opening reactions of the chiral cardioprotective agent (+) (S)-ICRF-187 and its (−) (R)-enantiomer ICRF-186 by dihydropyrimidine amidohydrolase. Drug Metab. Dispos. 21:883–888.

    PubMed  CAS  Google Scholar 

  38. Schroeder, P. E., Davidson, J. N., and Hasinoff, B. B. (2002). Dihydroorotase catalyzes the ring-opening of the hydrolysis intermediates of the cardioprotective drug dexrazoxane (ICRF-187). Drug Metab. Dispos. 30:1431–1435.

    Article  PubMed  CAS  Google Scholar 

  39. Schroeder, P. E., and Hasinoff, B. B. (2002). The doxorubicin-cardioprotective drug dexrazoxane undergoes metabolism in the rat to its metal ion-chelating form ADR-925. Cancer Chemother. Pharmacol. 50:509–513.

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Faculty of Pharmacy, University of Manitoba, R3T 2N2, Winnipeg, Manitoba, Canada

    Brian B. Hasinoff, Kareena L. Schnabl & Daywin Patel

  2. Department of Chemistry, Kenyon College, 43022, Gambier, OH

    Rosemary A. Marusak

  3. Department of Zoology, University of Manitoba, Winnipeg, Manitoba, Canada

    Erwin Huebner

Authors
  1. Brian B. Hasinoff
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Kareena L. Schnabl
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Rosemary A. Marusak
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Daywin Patel
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Erwin Huebner
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Brian B. Hasinoff.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Hasinoff, B.B., Schnabl, K.L., Marusak, R.A. et al. Dexrazoxane (ICRF-187) protects cardiac myocytes against doxorubicin by preventing damage to mitochondria. Cardiovasc Toxicol 3, 89–99 (2003). https://doi.org/10.1385/CT:3:2:89

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1385/CT:3:2:89

Key Words

Search

Navigation